Anti-VE GF Therapy Revived by c-Met Inhibition, But Is c-Met the Answer?

Cancer Discovery

Volumn 2, Issue 3, 2012, Pages 211-213

  Lynn, Kristi D ^a   Brekken, Rolf A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; CABOZANTINIB; FORETINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; ANILIDE; NEUTRALIZING ANTIBODY; PYRIDINE DERIVATIVE; VASCULOTROPIN A;

ARTICLE; CANCER INVASION; CANCER SURVIVAL; HYPOXIA; METASTASIS; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; DRUG ANTAGONISM; HUMAN; NEUROENDOCRINE TUMOR; NOTE; PANCREAS TUMOR;

ANILIDES; ANIMALS; ANTIBODIES, NEUTRALIZING; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865811095     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0037     Document Type: Article

References (16)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
2. Tanne JH. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ 2011;343:d7684.
3. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
4. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
5. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007;104:17069-74.
6. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21.
7. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
8. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery 2012;2:270-87.
9. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011;71:4758-68.
10. Couto SS, Forrest WF, Cheng JH, et al. Anti-VEGF monoclonal antibody therapy in genetically engineered mouse tumor models: efficacy, survival, and metastasis. Angiogenesis: advances in basic science and therapeutic applications: Keystone Symposia; 2012. Available from: http://www.keystonesymposia.org/meetings/view Meetings.cfm?MeetingID=1141.
11. Kusters B, Kats G, Roodink I, Verrijp K, Wesseling P, Ruiter DJ, et al. Micronodular transformation as a novel mechanism of VEGFA-induced metastasis. Oncogene 2007;26:5808-15.
12. Kanai T, Konno H, Tanaka T, et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998;77:933-6.
13. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007; 104:2837-42.
14. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing antivascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161:960-3.
15. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002;8:2714-24.
16. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007;13:4201-8.